Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 26 studies | 26% ± 10% | |
smooth muscle cell | 21 studies | 22% ± 7% | |
fibroblast | 16 studies | 23% ± 7% | |
pericyte | 12 studies | 22% ± 5% | |
astrocyte | 11 studies | 34% ± 16% | |
B cell | 9 studies | 20% ± 6% | |
glutamatergic neuron | 8 studies | 37% ± 24% | |
capillary endothelial cell | 8 studies | 19% ± 4% | |
endothelial cell of lymphatic vessel | 8 studies | 23% ± 4% | |
macrophage | 8 studies | 26% ± 6% | |
CD4-positive, alpha-beta T cell | 7 studies | 20% ± 6% | |
natural killer cell | 7 studies | 18% ± 3% | |
type I pneumocyte | 7 studies | 23% ± 5% | |
GABAergic neuron | 7 studies | 35% ± 20% | |
oligodendrocyte | 7 studies | 26% ± 8% | |
oligodendrocyte precursor cell | 7 studies | 26% ± 12% | |
conventional dendritic cell | 6 studies | 26% ± 8% | |
connective tissue cell | 6 studies | 23% ± 8% | |
epithelial cell | 6 studies | 37% ± 10% | |
adipocyte | 6 studies | 22% ± 4% | |
type II pneumocyte | 6 studies | 22% ± 7% | |
neuron | 5 studies | 39% ± 13% | |
microglial cell | 5 studies | 24% ± 5% | |
myofibroblast cell | 5 studies | 28% ± 8% | |
myeloid cell | 5 studies | 23% ± 3% | |
retinal rod cell | 5 studies | 18% ± 3% | |
dendritic cell | 5 studies | 27% ± 9% | |
goblet cell | 5 studies | 28% ± 12% | |
T cell | 5 studies | 19% ± 3% | |
classical monocyte | 4 studies | 20% ± 5% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 4 studies | 18% ± 2% | |
endothelial cell of artery | 4 studies | 17% ± 1% | |
plasma cell | 4 studies | 30% ± 10% | |
retina horizontal cell | 4 studies | 26% ± 6% | |
retinal cone cell | 4 studies | 26% ± 7% | |
cardiac muscle cell | 4 studies | 25% ± 1% | |
ciliated cell | 4 studies | 28% ± 8% | |
lymphocyte | 4 studies | 22% ± 2% | |
Mueller cell | 4 studies | 23% ± 7% | |
abnormal cell | 4 studies | 23% ± 10% | |
endothelial cell of vascular tree | 4 studies | 22% ± 7% | |
hepatocyte | 4 studies | 33% ± 12% | |
monocyte | 4 studies | 20% ± 3% | |
basal cell | 4 studies | 26% ± 10% | |
naive B cell | 4 studies | 19% ± 3% | |
interneuron | 4 studies | 42% ± 21% | |
plasmacytoid dendritic cell | 4 studies | 27% ± 5% | |
hematopoietic precursor cell | 3 studies | 22% ± 3% | |
non-classical monocyte | 3 studies | 21% ± 5% | |
retinal bipolar neuron | 3 studies | 26% ± 6% | |
pro-B cell | 3 studies | 24% ± 3% | |
amacrine cell | 3 studies | 34% ± 7% | |
mononuclear phagocyte | 3 studies | 21% ± 7% | |
OFF-bipolar cell | 3 studies | 21% ± 5% | |
rod bipolar cell | 3 studies | 20% ± 3% | |
CD8-positive, alpha-beta T cell | 3 studies | 19% ± 5% | |
regulatory T cell | 3 studies | 20% ± 3% | |
ependymal cell | 3 studies | 35% ± 13% | |
vein endothelial cell | 3 studies | 23% ± 8% | |
alveolar macrophage | 3 studies | 20% ± 6% | |
transit amplifying cell | 3 studies | 24% ± 11% | |
mesothelial cell | 3 studies | 30% ± 12% | |
granule cell | 3 studies | 25% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 3485.09 | 459 / 459 | 100% | 43.83 | 1118 / 1118 |
liver | 100% | 1780.75 | 226 / 226 | 100% | 20.83 | 406 / 406 |
ovary | 100% | 3760.06 | 180 / 180 | 100% | 26.26 | 430 / 430 |
prostate | 100% | 5720.72 | 245 / 245 | 100% | 51.16 | 502 / 502 |
thymus | 100% | 3490.45 | 653 / 653 | 100% | 38.95 | 605 / 605 |
esophagus | 100% | 5812.62 | 1444 / 1445 | 100% | 22.63 | 183 / 183 |
lung | 100% | 3569.42 | 577 / 578 | 100% | 31.85 | 1155 / 1155 |
intestine | 100% | 7897.20 | 966 / 966 | 100% | 26.79 | 526 / 527 |
uterus | 100% | 5586.94 | 170 / 170 | 100% | 35.98 | 458 / 459 |
bladder | 100% | 5587.62 | 21 / 21 | 100% | 27.29 | 502 / 504 |
brain | 100% | 3216.14 | 2629 / 2642 | 100% | 46.21 | 705 / 705 |
stomach | 99% | 3694.40 | 357 / 359 | 100% | 26.79 | 286 / 286 |
kidney | 100% | 2195.04 | 89 / 89 | 99% | 28.14 | 893 / 901 |
adrenal gland | 100% | 2642.69 | 257 / 258 | 98% | 24.39 | 226 / 230 |
pancreas | 98% | 1505.39 | 322 / 328 | 99% | 28.94 | 177 / 178 |
skin | 100% | 2704.14 | 1805 / 1809 | 96% | 24.26 | 451 / 472 |
adipose | 100% | 3525.45 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6271.68 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 32.27 | 29 / 29 |
spleen | 100% | 2997.94 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 27.27 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.06 | 1 / 1 |
muscle | 100% | 2619.06 | 799 / 803 | 0% | 0 | 0 / 0 |
heart | 95% | 2377.55 | 822 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 89% | 15.16 | 71 / 80 |
peripheral blood | 83% | 1990.38 | 769 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030162 | Biological process | regulation of proteolysis |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0031463 | Cellular component | Cul3-RING ubiquitin ligase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0042802 | Molecular function | identical protein binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005515 | Molecular function | protein binding |
GO_0140678 | Molecular function | molecular function inhibitor activity |
Gene name | SPOP |
Protein name | Speckle type BTB/POZ protein Speckle-type POZ protein (HIB homolog 1) (Roadkill homolog 1) |
Synonyms | |
Description | FUNCTION: Component of a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates the ubiquitination of target proteins, leading most often to their proteasomal degradation. In complex with CUL3, involved in ubiquitination and proteasomal degradation of BRMS1, DAXX, PDX1/IPF1, GLI2 and GLI3. In complex with CUL3, involved in ubiquitination of MACROH2A1 and BMI1; this does not lead to their proteasomal degradation. Inhibits transcriptional activation of PDX1/IPF1 targets, such as insulin, by promoting PDX1/IPF1 degradation. The cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex containing homodimeric SPOP has higher ubiquitin ligase activity than the complex that contains the heterodimer formed by SPOP and SPOPL. Involved in the regulation of bromodomain and extra-terminal motif (BET) proteins BRD2, BRD3, BRD4 stability . Plays an essential role for proper translation, but not for their degradation, of critical DNA replication licensing factors CDT1 and CDC6, thereby participating in DNA synthesis and cell proliferation . Regulates interferon regulatory factor 1/IRF1 proteasomal turnover by targeting S/T-rich degrons in IRF1 . Facilitates the lysosome-dependent degradation of enterovirus EV71 protease 2A by inducing its 'Lys-48'-linked polyubiquitination, which ultimately restricts EV71 replication . Acts as an antiviral factor also against hepatitis B virus/HBV by promoting ubiquitination and subsequent degradation of HNF1A . In turn, inhibits HBV transcription and replication by preventing HNF1A stimulating activity of HBV preS1 promoter and enhancer II . . |
Accessions | ENST00000505581.5 ENST00000510476.5 ENST00000504212.5 ENST00000659760.1 A0A590UJA7 ENST00000503676.5 ENST00000347630.6 D6RA79 ENST00000665825.1 D6RDG8 ENST00000504102.6 ENST00000513080.6 D6RD94 O43791 ENST00000671445.1 ENST00000514121.6 H0Y977 D6RIS7 ENST00000509869.5 D6RFL7 D6RGZ4 ENST00000393328.6 ENST00000508805.5 D6RBR3 ENST00000451526.6 ENST00000506399.5 ENST00000515508.6 ENST00000509079.6 ENST00000507970.5 |